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ABSTRACT
A 56-year-old woman was referred to our hospital because of dyspnea, wheezing, and a productive cough.
Eight years before presentation, bronchial asthma was diagnosed and the patient received inhaled corticoster-
oids plus antiasthmatic agents (a long-acting inhaled β2-agonist, leukotriene modifiers, and theophylline).
Chest radiography showed small diffuse nodular shadows, and a computed tomographic scan showed thicken-
ing of the bronchi and bronchioles, with diffuse centrilobular nodules in both lung fields. A blood test and micro-
scopic examination of the bronchoalveolar fluid revealed marked eosinophilia. Transbronchial lung biopsy and
transbronchial biopsy showed eosinophilic bronchitis and bronchiolitis. After treatment with oral prednisolone
(40 mg daily) and inhaled corticosteroids, the symptoms, blood eosinophilia, and radiographic findings im-
proved. Recently, several similar cases of eosinophilic bronchiolitis have been reported. Studies of further
cases and elucidation of the pathophysiology of eosinophilic bronchiolitis are necessary to establish a concept
for this disease and to determine whether it should be classified as a subtype of bronchial asthma or as a dis-
tinct entity.
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INTRODUCTION
Eosinophilic lung disease shows diverse pathological
characteristics and chest imaging findings. It can be
caused by various factors, including parasitic and fun-
gal infections, allergies, drugs, radiation, hazardous
materials, smoking, vasculitis, or can be idiopathic.
Among potential causes, allergic bronchopulmonary
mycosis and allergic granulomatous vasculitis
Churg-Strauss syndrome are also associated with
bronchial asthma. In 2001, chronic eosinophilic bron-
chiolitis was proposed as an atypical eosinophilic lung
disease.1 Subsequently, similar cases have been ac-
companied by asthma-like symptoms and dyspnea,
suggesting an association with bronchial asthma.2-5
We describe a case of bronchial asthma that showed
diffuse centrilobular granular shadows and airway
thickening on computed tomography (CT) of the
chest and was diagnosed as eosinophilic bronchitis
bronchiolitis on histopathological examination.
CLINICAL SUMMARY
The patient was a 56-year-old woman. Her main
symptoms were dyspnea, wheezing, and a productive
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Fig. 1 a. CXR on admission showed difuse granular shad
ows in bilateral lung fields. b. Chest HRCT scan obtained on 
admission showed difuse centrilobular nodules in both lung 
fields in association with thickening of the bronchi and 
bronchioles.
b
acough. The patient had a history of acute appendicitis
at 20 years of age and sinusitis at 52 years. The family
history was not relevant to the present disorder. As
for lifestyle, the patient did not smoke or drink alco-
hol. She kept two dogs as pets outside of her home
and was employed as an office worker.
Bronchial asthma was diagnosed 8 years previ-
ously and the patient had been treated by a local phy-
sician. She had been hospitalized 4 times for asthma
attacks. Since November 2005, the patient received
inhaled corticosteroids, a long-acting inhaled β2-
agonist, leukotriene modifiers, and theophylline in ac-
cordance with guidelines for the treatment of
asthma.6 Because the patient had frequent exacerba-
tions, she was referred to our hospital in July 2006.
The physical findings on admission were as fol-
lows: height, 155.1 cm; body weight, 57.0 kg; body
mass index, 23.7; body temperature, 36.8℃; blood
pressure, 12080 mmHg; pulse rate, 80 beatsminute;
respiratory rate, 24 timesminute; and SaO2, 94%.
The patient’s consciousness was clear. Grade III
wheezing was present in both lung fields, with no car-
diac murmur. The abdomen was flat and soft, with no
tenderness. There was no edema in the extremities.
The neurological findings were normal.
The results of blood tests were as follows: white
cell count, 8.2 × 109L (neutrophils, 40.9%; eosino-
phils, 35.4%, lymphocytes, 19.3%; and monocytes,
4.0%); hemoglobin, 13.7 gdL; hematocrit, 41.1%;
platelets, 329 × 109L; serum total protein, 7.4 gdL;
serum aspartate aminotransferase, 16 UL; serum
alanine aminotransferase, 10 UdL; serum lactate de-
hydrogenase, 190 UL; C-reactive protein, 0.44 mg
dL; antinuclear antibody titer, 1 : 80; myeloperoxidase
antineutrophil cytoplasmic antibody titer, <10 EU;
proteinase 3-antineutrophil cytoplasmic antibody
titer, <10 EU; and IgE, 411 IUmL. Anti-SS-AB anti-
body, aspergillus antibody, aspergillus-precipitating
antibody, and human T-cell leukemia virus type-1 an-
tibody were all negative. Radioallergosorbent testing
showed that specific IgE antibodies to house dust,
Dermatophagoides pternysinus, aspergillus, candida,
alternaria, cedar, ragweed, wormwood, orchard
grass, cat dander, dog dander, and moth were nega-
tive. Blood gas values while the patient was breathing
room air were as follows: pH, 7.43; PaCO2, 31.8 Torr;
and PaO2, 69.8 Torr. Sputum cultures showed normal
flora.
The results of lung function tests were as follows:
VC, 1.84 L (74.1%); FEV1, 0.72 L (35.1%); FEV1% (G),
47.4%; and %DLCO, 77.1%. On airway hyperreactivity
testing (acetylcholine inhalation test), the PC20 was
2800 μgmL. The exhaled nitric oxide concentration
(eNO) was 184.4 ppb. The CXR and the HRCT find-
ings on admission are shown in Figure 1. On bron-
choscopy the numbers of cells in the bronchoalveolar
lavage (BAL) fluid were as follows: total cell count,
12.6 × 105mL; monocytes, 22.9%; neutrophils, 0.4%;
lymphocytes, 7.4%; and eosinophils, 68.7%. Histopa-
thological findings of transbronchial lung biopsy
(TBLB) specimens and transbronchial biopsy (TBB)
specimens are shown in Figure 2.
COURSE AFTER ADMISSION
The patient had symptoms of bronchial asthma such
as dyspnea, wheezing, and hypoxemia on admission.
Chest imaging studies showed bronchial and bron-
chiolar lesions. Since the patient had peripheral-blood
eosinophilia, a diagnosis of eosinophilic bronchiolitis,
recently proposed as a distinct clinical entity, was sus-
pected. Bronchoscopy was performed on the 6th day.
There was an increased total cell count in the BAL
fluid, and the proportion of eosinophils had risen by
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Fig. 2 Photomicrographs of TBB and TBLB specimen. a. 
Significant infiltration of eosinophil is observed in the bron
chial mucosal and submucosal membrane region (HE stain
ing ×100). b. Goblet cel metaplasia is observed in the 
bronchiolar epithelium, and eosinophil/monocyte infiltration 
is observed in the subepithelial region (HE staining ×200). c. 
Epithelial detachment, basal membrane thickening, and 
eosinophil/mononuclear lymphocyte infiltration are observed 
in the membranous bronchiole (HE staining ×200).
b
a
c
68.7%. TBLB and TBB suggested bronchitisbron-
chiolitis with eosinophilic infiltration. There was no
evidence of allergy to aspergillus or other fungi and
no peripheral neuritis or vasculitis. Allergic bron-
chopulmonary mycosis and allergic granulomatous
vasculitis were thus unlikely. Since airway hyperreac-
tivity was confirmed on an acetylcholine inhalation
test, bronchial asthma associated with eosinophilic
bronchiolitis was diagnosed. The patient received flu-
ticasone (400 μgd) since the date of admission, and
prednisolone (40 mgd) was started immediately af-
ter bronchoscopy. After starting treatment, symp-
toms improved dramatically. Dyspnea and wheezing
decreased in several days and oxygen inhalation was
stopped after 5 days of prednisolone treatment. The
peripheral eosinophil count decreased from 2902 ×
106L to 47 × 106L after 7 days of treatment. There
was also improvement in the shadows on the chest
images, as well as lung function. The eNO level de-
creased from 184.4 to 42.9 ppb. The dose of predniso-
lone was tapered, and hydrofluoroalkane (HFA)-
beclomethasone (200 μgd) was added to fluticasone.
The condition of the patient improved substantially,
and she was discharged.
DISCUSSION
Recently, several cases of eosinophilic bronchiolitis
have been reported in Japan (Table 1). Common
characteristics include bronchiolitis with eosinophilic
infiltration (on imaging studies and histopathological
examination), obstructive ventilatory impairment, air-
way hyperreactivity, and blood and BAL-fluid eosino-
philia. Clinically, eosinophilic bronchiolitis must be
differentiated from various other diseases associated
with eosinophilic infiltration and from various types of
bronchiolitis and bronchial asthma. Although the ra-
diographic findings in our patient, who had a history
of sinusitis, resembled those in diffuse panbronchioli-
tis (DPB), the histological findings were not consis-
tent with DPB, which is characterized by accumula-
tions of mononuclear cells (predominantly lympho-
cytes, plasma cells and foamy histiocytes) in the walls
of respiratory bronchioles. The histological evalu-
ation of TBLB specimens such as those obtained in
our patient has inherent limitations as compared with
lung biopsy specimens obtained surgically, in which
the walls of bronchioles can undergo complete micro-
scopical examination. Inhaled steroids alone are not
adequately effective in many patients; a moderate
dose of oral steroids is usually very effective. How-
ever, decreasing the dose of steroids often triggers a
recurrence, suggesting that long-term therapy with a
maintenance dose of steroids is necessary.
Our patient did not respond to guideline-based
treatment for asthma6 at other clinics. However, the
patient showed airway hyperreactivity, and the eNO
level had increased to 184.4 ppb at admission.7 The
clinical features and the results of laboratory and
histopathological examinations led to a diagnosis of
bronchial asthma associated with eosinophilic bron-
chiolitis. In 5 previously reported cases (Table 1), not
including the present one, biopsy specimens of the
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Table 1 Clinical characteristics of patients with EB reported in previous studies, including our patient†
Year
Author
OutcomeTherapy
Method
of
biopsy
Radiologic
findings (CT)
Time to
EB
onset
Bronchial
asthma
Signs
and
symptoms
Case
Age
Sex
2001
Takayanagi
 et al 1
Recurence
Dose of PSL 
decreased
Oral PSL
40 mg
SurgicalCentrilobular
nodules
Thickening of
bronchi, bronchioles
3 years－
(Airway hyper
reactivity +)
Dyspnea,
wheeze,
cough
1
46
M
2003
Nakagome
 et al 2
Recurence
Dose of PSL 
decreased
Oral PSL
30 mg
ICS
SurgicalCentrilobular
nodules
Thickening of
bronchi, bronchioles
3 months－
(Airway hyper
reactivity +)
Dyspnea,
wheeze,
cough
2
23
M
2004
Nagata
et al 3
Recurence
Dose of PSL 
decreased
mPSL 80 mg 
d.i.v.
Oral PSL, ICS
SurgicalCentriacinar nodules
Thickening of
bronchi, bronchioles
4 years+
Dyspnea,
cough
3
62
F
2006
Tsuburai
et al 4
No
recurence
Hydrocortisone
300 mg d.i.v.
Oral PSL
30 mg
SurgicalCentrilobular
nodules
Bronchiectasis
Mucoid impaction
5 years+
Chest 
shadow
4
50
F
2006
Morimoto
 et al 5
Recurence
Dose of PSL 
decreased
Oral PSL
30 mg
SurgicalCentrilobular
nodules
Thickening of 
bronchi 
6 months+
Dyspnea,
cough
5
42
M
Present 
case
No
recurence
Oral PSL
40 mg
ICS
TBLBCentrilobular
nodules
Thickening of
bronchi, bronchioles
8 years+Dyspnea,
wheeze,
cough
 6†
56
F
EB, eosinophilic bronchiolitis; PSL, prednisolone; mPSL, methylprednisolone; ICS, inhaled corticosteroids; d.i.v., drip intravenous 
infusion.
lung were obtained under video-assisted thora-
coscopic guidance. This is a very useful technique for
obtaining a sufficient quantity of peripheral lung lob-
ules for histological examination, but is more invasive
than bronchoscopic lung biopsy. Fortunately, we
could make a diagnosis by bronchoscopic TBLB and
TBB. The patient responded to treatment with 40 mg
of oral prednisolone and is currently also receiving
fluticasone and HFA-beclomethasone (considering
delivery to the peripheral airways). The dosage of
oral prednisolone was decreased to 2.5 mg on alterna-
tive days.
Since the late 1990’s, eosinophilic airway inflamma-
tion, a cardinal sign of bronchial asthma, has been
confirmed in the peripheral as well as the central air-
ways.8,9 The bronchiolar region may also be involved
in asthma.10 However, cases showing centrilobular
granular shadows on chest CT scans have not been
studied in detail. Eosinophilic bronchiolitis was first
reported in 2001,1 and several other similar cases
were subsequently reported in Japan.2-5 The present
case was introduced because we believe that it satis-
fies the proposed diagnostic criteria. Studies of addi-
tional cases of eosinophilic bronchiolitis are neces-
sary to establish the concept for this disease and to
further elucidate its pathophysiology and thereby de-
termine whether eosinophilic bronchiolitis should be
classified as a subtype of bronchial asthma or as a dis-
tinct entity.
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